Skip to navigation Skip to content


July 25, 2018

A shift in focus: Lorson moves basic research to drug development

By Roger Meissen & Erica Overfelt | Bond LSC It takes a lot to move a discovery from lab bench to an application that can provide therapeutic benefits to those suffering from disease. Bond LSC’s Chris Lorson is making moves to bridge that gap with the start of Shift Pharmaceuticals. With its formation in March…